Company Overview
About Synthekine
Synthekine is a clinical-stage biotechnology company engineering next-generation cytokine therapeutics designed to harness the immune system's most powerful signaling molecules against cancer and autoimmune disease — without the severe toxicities that have historically limited cytokine drugs. Cytokines like interleukin-2 (IL-2) are known to activate potent anti-tumor immune responses, but their systemic pleiotropic effects cause dose-limiting toxicities when administered as conventional drugs. Synthekine's protein engineering platforms create partially agonized or receptor-selective cytokine variants that stimulate only the desired immune cell populations, dramatically improving the therapeutic window.
Business Model & Competitive Advantage
Founded in 2018 and headquartered in Menlo Park, California, Synthekine has raised $289M in total funding, including a $100M Series C led by The Column Group in January 2023, with participation from Bain Capital Life Sciences and other institutional biotech investors. The company's lead program, STK-012 — a first-in-class α/β-IL-2 receptor biased partial agonist — is being evaluated in the SYNERGY-101 Phase 2 randomized clinical trial in combination with pembrolizumab and chemotherapy for first-line PD-L1 negative non-squamous non-small cell lung cancer (NSCLC). Phase 1b data presented at SITC 2025 showed a 50% objective response rate in this population, comparing favorably to the 23–32% expected with standard of care.
Competitive Landscape 2025–2026
In September 2024, the FDA granted Fast Track Designation to Synthekine's SYNCAR-001 + STK-009 program — combining a CD19 CAR-T cell therapy with an orthogonal IL-2 — for the treatment of severe, refractory systemic lupus erythematosus, making it one of the few BCI programs targeting an autoimmune indication without requiring lymphodepletion. Synthekine's approach positions it at the forefront of next-generation immunotherapy, where engineered cytokines are expected to augment checkpoint inhibitors, CAR-T therapies, and other modalities.
Key Differentiators
Strong Challenger
Synthekine is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare Synthekine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Synthekine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Synthekine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Synthekine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →